REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing

MaxCyteAnnouncement

31/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241031:nRSe3072Ka&default-theme=true

RNS Number : 3072K  MaxCyte, Inc.  31 October 2024

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Exercise of options and PDMR dealing

 

ROCKVILLE, MD, October 31, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT),
a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics and to support innovative, cell-based
research, announces that on 28 October 2024, as per a filing lodged with the
U.S. Securities and Exchange Commission, John Johnston, a Non-Executive
Director of the Company, exercised options over 3,000 shares of common stock
of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The
3,000 new shares of Common Stock were issued pursuant to the Company's
existing its block admission facility and were sold by John Johnston at a
price range between $3.700 and $3.740 per Common Stock ("Sale"). The sold
shares represent approximately 0.9% of John Johnston's total equity and
option holdings in the Company's stock capital, respectively.

 

Following the Exercise and Sale, John Johnston holds 120,583 shares of
Common Stock representing 0.1% of the issued stock capital of the Company.
Following the Exercise, John Johnston holds a further 180,918 options over
Common Stock and 21,367 restricted stock units.

 

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading
plan adopted by John Johnston on 19 December 2023 relating solely to the sale
of shares acquired from exercise of options that expire on 14 July 2027.

 

 

MaxCyte Contacts:

 

 US IR Adviser

 Gilmartin Group                               +1 415-937-5400

 David Deuchler, CFA                           ir@maxcyte.com (mailto:ir@maxcyte.com)

 Nominated Adviser and Joint Corporate Broker

 Panmure Liberum                               +44 (0)20 7886 2500

 Emma Earl / Freddy Crossley

 Corporate Broking

 Rupert Dearden

 UK IR Adviser                                 +44 (0)203 709 5700

 ICR Healthcare                                maxcyte@icrhealthcare.com

 Mary-Jane Elliott

 Chris Welsh

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmE1MjQ6ZjkwYTM4NTFkYzFjZTE4MDc3MzEzMDUxMzdhY2YwMjI4NmExYzRmM2IyYTQ4MGRkNjJhMTZiYmUyNzZkMWE4NDpwOlQ6Rg)
and follow us on X
(https://protect.checkpoint.com/v2/___https:/twitter.com/MaxCyte_info___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmNlODY6NGQ3NmQ0ODY5ZWMwZGM2ZWY3YWE0YzdmMzljY2UyODM4ZTExMGI5OWRjODhlYjk5NmI3ZjcyZTNlNTIxZGE4ZDpwOlQ6Rg)
and LinkedIn
(https://protect.checkpoint.com/v2/___https:/www.linkedin.com/company/maxcyte-inc-/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozM2I1YTVmN2I2YTExNzdhYjJiYWQzMzY2ZWJlM2NkNzo2OmE5Yjg6ODI4ODYyMDRkZDU5YTY0MjUyMzY1NGQwMjczZDA2NTM5YTI1MDcxM2Y4NjgyNWUxODM5YTcxMTc4ZDJkYmRiMDpwOlQ6Rg)
.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         John Johnston

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         MaxCyte, Inc.

 b)   LEI                                                          54930053YHXULRFCU991

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common Stock of $0.01 each

      Identification code                                          US57777K1060

 b)   Nature of the transaction                                    Exercise of Options over common stock

 c)   Price(s) and volume(s)

                                                                                     Exercise Price(s)  Volume(s)
                                                                                     $2.926             3,000

 d)   Aggregated information

      - Aggregated volume                                          3,000

      - Price                                                      $2.926

 e)   Date of the transaction                                      28 October 2024

 f)   Place of the transaction                                     US Stock Exchange, Nasdaq

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         John Johnston

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         MaxCyte, Inc.

 b)   LEI                                                          54930053YHXULRFCU991

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common Stock of $0.01 each

      Identification code                                          US57777K1060

 b)   Nature of the transaction                                    Sale of common stock

 c)   Price(s) and volume(s)

                                                                                     Exercise Price(s)  Volume(s)
                                                                                     $3.7000            200
                                                                                     $3.7100            383
                                                                                     $3.7150            400
                                                                                     $3.7200            450
                                                                                     $3.7210            200
                                                                                     $3.7250            300
                                                                                     $3.7300            100
                                                                                     $3.7310            200
                                                                                     $3.7350            700
                                                                                     $3.7400            67

 d)   Aggregated information

      - Aggregated volume                                          3,000

      - Price                                                      $3.7223

 e)   Date of the transaction                                      28 October 2024

 f)   Place of the transaction                                     US Stock Exchange, Nasdaq

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHMMBRTMTAJBPI